Cincinnati startup key player in $330M Blackstone-backed drug collaboration

A red-hot Cincinnati startup is at the center of a new $300 million-plus collaboration between drugmaker Sanofi and global investment group Blackstone Life Sciences that could prove a significant advancement for the local company’s business.

Blackstone in March pledged up to $330 million (€300 million) to fund clinical trials and related costs for a subcutaneous formulation (delivered through the skin) of Sanofi drug’s Sarclisa for patients with multiple myeloma, an incurable cancer of the plasma cells.

Click here to read the complete story.

Story excerpt provided by Cincy Inno

Written by Liz Engel.

Originally published April 10, 2022.